Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Selinde S. Wind; Manon A. A. Jansen; Melanie Rijsbergen; Michiel J. van Esdonk; Dimitrios Ziagkos; Wing C. Cheng; Tessa Niemeyer-van der Kolk; John Korsten; Agnieszka Gruszka; Debora Schmitz-Rohmer; David Bonnel; Raphael Legouffe; Florian Barré; Marcel W. Bekkenk; Ellen R. M. de Haas; Koen D. Quint; Harald Schnidar; Melanie Rolli; Henk Johan Streefkerk; Jacobus Burggraaf; Maarten H. Vermeer; Robert Rissmann

doi:10.3390/cancers15051485

Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Selinde S. Wind, Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, David Bonnel, Raphael Legouffe, Florian Barré, Marcel W. Bekkenk, Ellen R. M. de Haas, Koen D. Quint, Harald Schnidar, Melanie Rolli, Henk Johan Streefkerk, Jacobus BurggraafMaarten H. Vermeer, Robert Rissmann^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

Original language	English
Article number	1485
Journal	Cancers
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/cancers15051485
Publication status	Published - 1 Mar 2023

Access to Document

10.3390/cancers15051485

Cite this

Wind, S. S., Jansen, M. A. A., Rijsbergen, M., van Esdonk, M. J., Ziagkos, D., Cheng, W. C., Niemeyer-van der Kolk, T., Korsten, J., Gruszka, A., Schmitz-Rohmer, D., Bonnel, D., Legouffe, R., Barré, F., Bekkenk, M. W., de Haas, E. R. M., Quint, K. D., Schnidar, H., Rolli, M., Streefkerk, H. J., ... Rissmann, R. (2023). Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). Cancers, 15(5), [1485]. https://doi.org/10.3390/cancers15051485

@article{2c9ed4a0c5fa4d2aa168ec2af1d95948,

title = "Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)",

abstract = "The authors wish to make the following corrections to this paper [1]: 1. {\textquoteleft}Harald Schnidar{\textquoteright} was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.",

author = "Wind, {Selinde S.} and Jansen, {Manon A. A.} and Melanie Rijsbergen and {van Esdonk}, {Michiel J.} and Dimitrios Ziagkos and Cheng, {Wing C.} and {Niemeyer-van der Kolk}, Tessa and John Korsten and Agnieszka Gruszka and Debora Schmitz-Rohmer and David Bonnel and Raphael Legouffe and Florian Barr{\'e} and Bekkenk, {Marcel W.} and {de Haas}, {Ellen R. M.} and Quint, {Koen D.} and Harald Schnidar and Melanie Rolli and Streefkerk, {Henk Johan} and Jacobus Burggraaf and Vermeer, {Maarten H.} and Robert Rissmann",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = mar,

day = "1",

doi = "10.3390/cancers15051485",

language = "English",

volume = "15",

journal = "Cancers (Basel)",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

Wind, SS, Jansen, MAA, Rijsbergen, M, van Esdonk, MJ, Ziagkos, D, Cheng, WC, Niemeyer-van der Kolk, T, Korsten, J, Gruszka, A, Schmitz-Rohmer, D, Bonnel, D, Legouffe, R, Barré, F, Bekkenk, MW, de Haas, ERM, Quint, KD, Schnidar, H, Rolli, M, Streefkerk, HJ, Burggraaf, J, Vermeer, MH & Rissmann, R 2023, 'Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)', Cancers, vol. 15, no. 5, 1485. https://doi.org/10.3390/cancers15051485

Correction : Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). / Wind, Selinde S.; Jansen, Manon A. A.; Rijsbergen, Melanie et al.

In: Cancers, Vol. 15, No. 5, 1485, 01.03.2023.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction

T2 - Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

AU - Wind, Selinde S.

AU - Jansen, Manon A. A.

AU - Rijsbergen, Melanie

AU - van Esdonk, Michiel J.

AU - Ziagkos, Dimitrios

AU - Cheng, Wing C.

AU - Niemeyer-van der Kolk, Tessa

AU - Korsten, John

AU - Gruszka, Agnieszka

AU - Schmitz-Rohmer, Debora

AU - Bonnel, David

AU - Legouffe, Raphael

AU - Barré, Florian

AU - Bekkenk, Marcel W.

AU - de Haas, Ellen R. M.

AU - Quint, Koen D.

AU - Schnidar, Harald

AU - Rolli, Melanie

AU - Streefkerk, Henk Johan

AU - Burggraaf, Jacobus

AU - Vermeer, Maarten H.

AU - Rissmann, Robert

PY - 2023/3/1

Y1 - 2023/3/1

N2 - The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

AB - The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149721907&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/36900424

U2 - 10.3390/cancers15051485

DO - 10.3390/cancers15051485

M3 - Comment/Letter to the editor

C2 - 36900424

SN - 2072-6694

VL - 15

JO - Cancers (Basel)

JF - Cancers (Basel)

IS - 5

M1 - 1485

ER -

Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC et al. Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510). Cancers. 2023 Mar 1;15(5):1485. doi: 10.3390/cancers15051485

Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Abstract

Access to Document

Other files and links

Cite this